Sessa Capital Reports 6.8% Insulet Stake Held By Its Funds And Accounts

The investment manager reported shared voting power over 4,689,185 shares and certified that the holding had no control-changing purpose.

Share
Sessa Capital Reports 6.8% Insulet Stake Held By Its Funds And Accounts

Sessa Capital IM, an investment manager, reported a 6.8% stake in Insulet, which makes Omnipod insulin-delivery systems, in a passive ownership disclosure filed with the SEC Monday. The holding comprised 4,689,185 shares in Sessa-managed funds and accounts as of September 30, 2026.

Shared Votes, Passive Purpose

Sessa jointly reported the holding with John Petry, the sole member and manager of Sessa Capital IM GP, its general partner. Both reported shared voting authority over the full holding, and neither reported sole voting authority. Their entries cover the same shares held by the funds and accounts.

The manager certified that the shares were bought and held as part of its ordinary business, without a purpose of changing or influencing Insulet's control.

The 6.8% calculation used Insulet's 69,354,199 outstanding common shares as of July 29, 2026. Insulet reported that share count in its second-quarter report filed August 5, 2026.

Omnipod's Reach And Manufacturing Expansion

Insulet's Omnipod delivers insulin continuously through a disposable, tubeless Pod worn on the body. Omnipod 5 combines that system with automated dosing software that works with third-party glucose monitors. The company also makes pods for Amgen's Neulasta Onpro kit.

Omnipod products are available in 25 countries. In the United States, Insulet primarily sells through wholesalers supplying pharmacies; elsewhere, it uses distribution partners or sells directly to consumers. Intermediaries accounted for 86% of worldwide Omnipod product sales in 2025.

Insulet makes its products in Acton, Massachusetts, and Johor, Malaysia. Its plans for a first Southeast Asian manufacturing site included approximately 400,000 square feet at AME's i-TechValley industrial park in Johor Baru, with a start expected in mid-2024.

AME group managing director Kelvin Lee Chai said negotiations with Insulet continued through the disruption of Covid-19. Insulet's market value was $10.6 billion as of 4:44 p.m. ET Monday.

Sources

More on Insulet

All Insulet (PODD) coverage →